Thursday, August 25, 2011

Medicare Part D Annual Enrollment Period Changed to October 15 Employers Must Send Notices Before October 15

LEGISLATIVE BRIEF

For 2011 and future years, the Medicare annual enrollment period for Part D (Prescription Drug coverage) will be October 15th ‐ December 7th. As a result, plan sponsors must provide Part D “creditable coverage” notices prior to October 15th of each year.

Most plan sponsors use the CMS Model Medicare Part D Notices of Creditable Coverage and Non‐Creditable Coverage to notify affected plan participants. These Model notices have been amended to reflect the October 15th date. Click here to access the model notices at the CMS website. 

Background 
The Medicare Modernization Act requires group health plan sponsors that offer prescription drug coverage to notify Medicare‐eligible plan participants (employees and dependents) as to whether their prescription drug coverage is “creditable coverage” – which means the coverage is expected to pay on average at least as much as the standard Medicare Part D prescription drug coverage.

These notices must be provided at least once annually, prior to the beginning of the Part D annual enrollment period and also if the employer provided coverage changes or if the individual requests a copy of the notice. In prior years the Medicare annual enrollment 
period for Part D began November 15th, so plan sponsors were required to provide “creditable coverage” notices prior to November 15th of each year. The federal Health Care Reform Act (Affordable Care Act) changed the Medicare annual enrollment period to October 15th – December 7th, so plan sponsors must now provide creditable coverage notices prior to October 15th of each year.

The Centers for Medicare and Medicaid Services (CMS) provide Model Medicare Part D Notices (available on the CMS website), which most employers use to notify Medicare‐eligible plan participants. These Model notices have now been amended to reflect the October 15th date. (The amended Model Notices say “For use on or after April 1, 2011” in the heading.)

The reason plan sponsors are required to provide Part D Notices is because a penalty will be imposed if an individual, after becoming eligible for Medicare Part D coverage, has a lapse of “creditable” prescription drug coverage for a period of at least 63 days. Additionally, such individuals may have to wait until the following October to join. An individual can elect either Medicare prescription drug coverage or other “creditable coverage” to avoid having a lapse in coverage. Thus, Medicare‐eligible participants in employer group health plans must know whether or not the employer group coverage is “creditable” so they do not unwittingly incur a late enrollment penalty.

Additional Details on the Disclosure Requirements 
Group health plan sponsors to whom this disclosure requirement applies include employers and Unions; multiple employer welfare arrangements (MEWAs); federal, state and local government employers; and churches.

The Part D Notice must be provided not only to Medicare‐eligible active working employees and their dependents, but also to participants who are retired, on COBRA, or disabled and covered under the employer’s prescription drug plan. 


Action Steps for Plan Sponsors 
If you provide prescription drug benefits through an insurance contract, you will also need input from your carrier as to whether or not your prescription drug coverage is creditable and to ensure that you correctly complete some of the information on your Part D Notice. 
Although the requirement is only that “Medicare eligible” individuals be provided this notice, employers often provide it to all plan participants and dependents because of the practical difficulty of knowing who may be Medicare‐eligible. 


Plan sponsors who use the CMS Model Notices should use the recently‐updated Model Notices which are available at the CMS website. Click here.

This Benefits Compliance bulletin is general in nature and is not intended or provided as legal advice or opinion in any particular case. If you have questions, contact your SRA Benefits Account Manager or benefits consultant. 

Thursday, August 18, 2011

Birth Control to be Covered Free of Co-Pays Beginning 2012

By David Wetzler, President, SRA Benefits
(August 2011) The US Department of Health and Human Services (HHS) just announced that beginning August 1, 2012, women in the United States will have their birth control covered, free of co-pays.
In addition to insurance coverage for birth control, the the HHS is also mandating a wide range of recommended preventive services without cost sharing, which includes:
  • Well-woman visits;
  • Screening for gestational diabetes;
  • Testing for the human papillonmavirus (HPV) as part of cervical cancer screening for women age 30 and older;
  • Counseling about sexually transmitted infections
  • Counseling and screening for HIV
  • Counseling on breast-feeding, including breast-feeding equipmentCounseling on interpersonal and domestic violence.
“New health plans will need to include these services without cost sharing for insurance policies with plans years beginning on or after August 1, 2012,”  the HHS said.   
For more information, see http://www.hhs.gov/news/press/2011pres/08/20110801b.html  or contact your SRA Benefits consultant.

Cheaper Drug Prices Become Reality As Patents Expire


By David Wetzler
President and Benefit Consultant

Over the next 14 months, generic drugs for seven of the world's best-selling drugs will become available as brand-name drug patents expire, including the top two: cholesterol fighter Lipitor and blood thinner Plavix.
Competition from generic drugs will decrease brand-name sales, causing drug prices to plummet for patients, taxpayers who help pay for prescription drugs through government prescription plans and employers who sponsor health plans.
Generic medicines are chemically equivalent to the original brand-name drugs and work just as well for nearly all patients. When a drug loses patent protection, often only one generic version is on sale for the first six months, so the price falls a little bit initially. Then, several other generic makers typically jump in, driving prices down dramatically. 
Last year, the average generic prescription cost $72, versus $198 for the average brand-name drug, according to consulting firm Wolters Kluwer Pharma Solutions. Those figures average all prescriptions, from short-term to 90-day ones.
Average copayments last year were $6 for generics, compared with $24 for brand-name drugs given preferred status by an insurer and $35 for nonpreferred brands, according to IMS Health.
Among the drugs that recently went off patent, Protonix, for severe heartburn, now costs just $16 a month for the generic, versus about $170 for the brand name. And of the top sellers that soon will have competition, Lipitor retails for about $150 a month, Plavix costs almost $200 a month and blood pressure drug Diovan costs about $125 a month. For those with drug coverage, their out-of-pocket costs for each of those drugs could drop below $10 a month.